NASDAQ:IRIX IRIDEX (IRIX) Stock Forecast, Price & News $2.20 +0.01 (+0.46%) (As of 04:35 PM ET) Add Compare Share Share Today's Range$2.17▼$2.3450-Day Range$1.33▼$2.2052-Week Range$1.31▼$2.74Volume116,591 shsAverage Volume24,216 shsMarket Capitalization$35.71 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media IRIDEX MarketRank™ ForecastAnalyst Rating0.00 Rating ScoreUpside/Downside8.7% Downside$2.00 Price TargetShort InterestHealthy0.51% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.48) to ($0.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.47 out of 5 starsComputer And Technology Sector585th out of 585 stocksElectromedical Equipment Industry22nd out of 22 stocks 0.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $2.00, IRIDEX has a forecasted downside of 8.7% from its current price of $2.19.Amount of Analyst CoverageIRIDEX has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.51% of the float of IRIDEX has been sold short.Short Interest Ratio / Days to CoverIRIDEX has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IRIDEX has recently increased by 13.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIRIDEX does not currently pay a dividend.Dividend GrowthIRIDEX does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IRIX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for IRIDEX this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IRIDEX insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of IRIDEX is held by insiders.Percentage Held by InstitutionsOnly 23.95% of the stock of IRIDEX is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IRIDEX are expected to grow in the coming year, from ($0.48) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IRIDEX is -4.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IRIDEX is -4.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIRIDEX has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IRIDEX (NASDAQ:IRIX) StockIRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.Read More IRIX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRIX Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comIRIDEX (NASDAQ:IRIX) Earns Buy Rating from Analysts at StockNews.comSeptember 14, 2023 | americanbankingnews.comIRIDEX (NASDAQ:IRIX) Coverage Initiated by Analysts at StockNews.comSeptember 22, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 13, 2023 | americanbankingnews.comIRIDEX (NASDAQ:IRIX) Share Price Passes Below Two Hundred Day Moving Average of $2.05August 30, 2023 | finanznachrichten.deIRIDEX Corporation: Iridex Announces Strategic Review to Unlock Shareholder ValueAugust 29, 2023 | seekingalpha.comIridex announces review of strategic alternatives, stock risesAugust 29, 2023 | finance.yahoo.comIridex Announces Strategic Review to Unlock Shareholder ValueAugust 11, 2023 | markets.businessinsider.comIridex Reports Second Quarter 2023 Financial ResultsSeptember 22, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.August 9, 2023 | markets.businessinsider.comIRIDEX earnings preview: what Wall Street is expectingAugust 9, 2023 | finance.yahoo.comWe Think IRIDEX (NASDAQ:IRIX) Needs To Drive Business Growth CarefullyJuly 28, 2023 | finance.yahoo.comIridex to Report Second Quarter Financial Results on August 10, 2023June 21, 2023 | finance.yahoo.comZacks Industry Outlook Highlights IPG Photonics and IRIDEXJune 8, 2023 | finance.yahoo.comIRIDEX Corporation's (NASDAQ:IRIX) Price Is Right But Growth Is LackingMay 18, 2023 | finance.yahoo.comIridex (IRIX) Is Attractively Priced Despite Fast-paced MomentumMay 11, 2023 | msn.comIridex: Q1 Earnings InsightsMay 11, 2023 | finance.yahoo.comIridex Reports First Quarter 2023 Financial ResultsApril 27, 2023 | finance.yahoo.comIridex to Report First Quarter Financial Results on May 11, 2023April 12, 2023 | finance.yahoo.comMultiple insiders bought IRIDEX Corporation (NASDAQ:IRIX) stock earlier this year, a positive sign for shareholdersMarch 13, 2023 | finance.yahoo.comIRIDEX Corporation (NASDAQ:IRIX) Q4 2022 Earnings Call TranscriptMarch 9, 2023 | finance.yahoo.comIridex Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 7, 2023 | finance.yahoo.comIridex to Present at the 35th Annual Roth ConferenceMarch 2, 2023 | finance.yahoo.comWe're Keeping An Eye On IRIDEX's (NASDAQ:IRIX) Cash Burn RateMarch 2, 2023 | finance.yahoo.comIridex Introduces New Research and Showcases Five Events at the AGS MeetingFebruary 23, 2023 | finance.yahoo.comIridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023January 10, 2023 | finance.yahoo.comIridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022December 6, 2022 | finance.yahoo.comIridex to Participate in Fireside Chat with Stifel Equity ResearchSee More Headlines Receive IRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter. Email Address IRIX Company Calendar Last Earnings8/10/2023Today9/22/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:IRIX CUSIPN/A CIK1006045 Webwww.iridex.com Phone(650) 940-4700Fax650-940-4710Employees130Year Founded1989Price Target and Rating Average Stock Price Forecast$2.00 High Stock Price Forecast$2.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside-9.1%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,550,000.00 Net Margins-13.78% Pretax Margin-13.69% Return on Equity-48.09% Return on Assets-18.82% Debt Debt-to-Equity RatioN/A Current Ratio2.53 Quick Ratio1.62 Sales & Book Value Annual Sales$56.97 million Price / Sales0.63 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book2.04Miscellaneous Outstanding Shares16,230,000Free Float15,223,000Market Cap$35.71 million OptionableNot Optionable Beta1.19 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. David I. Bruce (Age 64)Pres, CEO & Director Comp: $459.31kMr. Patrick Mercer (Age 51)Chief Operating Officer Comp: $385.51kMs. Leigh SalvoHead of Investor RelationsKey CompetitorsGigCapital5NYSE:GIAOne Stop SystemsNASDAQ:OSSData I/ONASDAQ:DAIOUTStarcomNASDAQ:UTSIFranklin WirelessNASDAQ:FKWLView All CompetitorsInstitutional OwnershipDimensional Fund Advisors LPSold 24,237 shares on 8/9/2023Ownership: 1.140%Isthmus Partners LLCBought 12,315 shares on 8/3/2023Ownership: 2.443%AMH Equity LtdBought 303,781 shares on 8/1/2023Ownership: 2.066%Perkins Capital Management Inc.Bought 5,500 shares on 7/21/2023Ownership: 0.315%View All Institutional Transactions IRIX Stock - Frequently Asked Questions What is IRIDEX's stock price forecast for 2023? 0 brokerages have issued 12-month price targets for IRIDEX's shares. Their IRIX share price forecasts range from $2.00 to $2.00. On average, they expect the company's stock price to reach $2.00 in the next twelve months. This suggests that the stock has a possible downside of 9.1%. View analysts price targets for IRIX or view top-rated stocks among Wall Street analysts. How have IRIX shares performed in 2023? IRIDEX's stock was trading at $2.01 on January 1st, 2023. Since then, IRIX shares have increased by 9.5% and is now trading at $2.20. View the best growth stocks for 2023 here. Are investors shorting IRIDEX? IRIDEX saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 61,200 shares, an increase of 13.3% from the August 15th total of 54,000 shares. Based on an average daily trading volume, of 29,300 shares, the short-interest ratio is currently 2.1 days. Approximately 0.5% of the shares of the company are short sold. View IRIDEX's Short Interest. When is IRIDEX's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our IRIX earnings forecast. How were IRIDEX's earnings last quarter? IRIDEX Co. (NASDAQ:IRIX) announced its earnings results on Thursday, August, 10th. The medical equipment provider reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.06. The medical equipment provider had revenue of $12.86 million for the quarter, compared to analysts' expectations of $14.23 million. IRIDEX had a negative trailing twelve-month return on equity of 48.09% and a negative net margin of 13.78%. What guidance has IRIDEX issued on next quarter's earnings? IRIDEX issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $55.00 million-$57.00 million, compared to the consensus revenue estimate of $58.05 million. What is Theodore A. Boutacoff's approval rating as IRIDEX's CEO? 7 employees have rated IRIDEX Chief Executive Officer Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among the company's employees. What other stocks do shareholders of IRIDEX own? Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include NVIDIA (NVDA), Trevena (TRVN), CTI BioPharma (CTIC), Agile Therapeutics (AGRX), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Lipocine (LPCN), Rigel Pharmaceuticals (RIGL) and SCYNEXIS (SCYX). What is IRIDEX's stock symbol? IRIDEX trades on the NASDAQ under the ticker symbol "IRIX." Who are IRIDEX's major shareholders? IRIDEX's stock is owned by many different institutional and retail investors. Top institutional investors include Isthmus Partners LLC (2.44%), AMH Equity Ltd (2.07%), Dimensional Fund Advisors LP (1.14%) and Perkins Capital Management Inc. (0.32%). Insiders that own company stock include Nandini Devi and Robert Earle Grove. View institutional ownership trends. How do I buy shares of IRIDEX? Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IRIDEX's stock price today? One share of IRIX stock can currently be purchased for approximately $2.20. How much money does IRIDEX make? IRIDEX (NASDAQ:IRIX) has a market capitalization of $35.71 million and generates $56.97 million in revenue each year. The medical equipment provider earns $-7,550,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis. How many employees does IRIDEX have? The company employs 130 workers across the globe. How can I contact IRIDEX? IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The official website for the company is www.iridex.com. The medical equipment provider can be reached via phone at (650) 940-4700, via email at investors@iridex.com, or via fax at 650-940-4710. This page (NASDAQ:IRIX) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IRIDEX Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.